11:41 AM EDT, 04/28/2025 (MT Newswires) -- Zentalis Pharmaceuticals ( ZNTL ) said Monday it has dosed the first patient in part 2 of the phase 2 clinical trial of azenosertib in ovarian cancer patients.

The company said it expects to release topline data from part 2 by the end of 2026, adding that a successful trial can support an accelerated approval, subject to Food and Drug Administration review.

Clinical data from part 1b of the study showed "clinically meaningful" results in patients with Cyclin E1+ platinum-resistant ovarian cancer, the company said.

Price: 1.42, Change: -0.01, Percent Change: -0.70